Literature DB >> 22708635

Association of 14 bp insertion/deletion polymorphism of the HLA-G gene in father with severe preeclampsia in Chinese.

Z Zhang1, Y Li, L L Zhang, L T Jia, X Q Yang.   

Abstract

Preeclampsia (PE), especially severe PE including early (before 34 weeks' gestation) and late (after 34 weeks' gestation) onset PE, is one of the leading causes of maternal and fetal mortality and morbidity. It is well known that abnormal human leukocyte antigen subtype G (HLA-G) expression may contribute to PE. In this study, we investigated allelic and genotypic frequencies of the 14 bp deletion/insert polymorphism in the 3(')-untranslated region (3(')-UTR) of the HLA-G gene in cases (120 pairs of mother-offspring, 82 couples, and 67 pairs of father-offspring with severe PE) and controls (158 pairs of mother-offspring, 87 couples, and 75 pairs of father-offspring with normal pregnancy). We found that the frequencies of the +14 bp/+14 bp HLA-G genotype of the offspring were significantly higher in the severe and early onset severe PE cases compared with controls, and the frequencies of the -14 bp/-14 bp HLA-G genotype of the offspring were significantly lower in the early onset severe PE cases compared with controls. The frequency of combined -14 bp/+14 bp mother/+14 bp/+14 bp offspring genotypes was significantly higher in the severe and early onset severe PE cases compared with controls, and the frequency of combined -14 bp/+14 bp mother/-14 bp/-14 bp offspring genotypes was significantly lower in the early onset severe PE cases compared with late onset severe PE cases. The frequency of combined -14 bp/-14 bp father/-14 bp/-14 bp offspring genotypes was significantly lower in the early onset severe PE cases compared with late onset severe PE cases and controls. In overview, the HLA-G 14 bp deletion/insert polymorphism is associated with severe PE in father-offspring, and its distribution is different between the early and late onset severe PE.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22708635     DOI: 10.1111/j.1399-0039.2012.01907.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  7 in total

Review 1.  HLA class Ib in pregnancy and pregnancy-related disorders.

Authors:  Gry Persson; Wenna Nascimento Melsted; Line Lynge Nilsson; Thomas Vauvert F Hviid
Journal:  Immunogenetics       Date:  2017-07-11       Impact factor: 2.846

Review 2.  Inhibition of host immune response in colorectal cancer: human leukocyte antigen-G and beyond.

Authors:  Marica Garziera; Giuseppe Toffoli
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 3.  Controlling the Immunological Crosstalk during Conception and Pregnancy: HLA-G in Reproduction.

Authors:  Line Lynge Nilsson; Snezana Djurisic; Thomas Vauvert F Hviid
Journal:  Front Immunol       Date:  2014-05-13       Impact factor: 7.561

Review 4.  HLA Class Ib Molecules and Immune Cells in Pregnancy and Preeclampsia.

Authors:  Snezana Djurisic; Thomas Vauvert F Hviid
Journal:  Front Immunol       Date:  2014-12-23       Impact factor: 7.561

5.  The Immunosignature of Mother/Fetus Couples in Gestational Diabetes Mellitus: Role of HLA-G 14 bp ins/del and PAPP-A A/C Polymorphisms in the Uterine Inflammatory Milieu.

Authors:  Miryam Martinetti; Fausta Beneventi; Cristina Capittini; Elena Locatelli; Margherita Simonetta; Chiara Cavagnoli; Irene De Maggio; Annalisa De Silvestri; Annamaria Pasi; Arsenio Spinillo
Journal:  Dis Markers       Date:  2017-06-01       Impact factor: 3.434

6.  HLA-G Polymorphisms Associated with HIV Infection and Preeclampsia in South Africans of African Ancestry.

Authors:  Wendy N Phoswa; Veron Ramsuran; Thajasvarie Naicker; Ravesh Singh; Jagidesa Moodley
Journal:  Biomed Res Int       Date:  2020-06-10       Impact factor: 3.411

Review 7.  The many faces of human leukocyte antigen-G: relevance to the fate of pregnancy.

Authors:  Mette Dahl; Snezana Djurisic; Thomas Vauvert F Hviid
Journal:  J Immunol Res       Date:  2014-03-04       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.